User: Guest  Login
More Searchfields
Simple search
Title:

High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma.

Document type:
journal article
Author(s):
Glass, B; Ziepert, M; Reiser, M; Freund, M; Trümper, L; Metzner, B; Feller, A; Loeffler, M; Pfreundschuh, M; Schmitz, N; German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL); Feller, AC; Hansmann, ML; Müler-Hermelink, HK; Moeller, P; Parwaresch, R; Stein, H; Glass, B; Schmitz, N; Schnabel, K; Rübe, C; Loeffler, M; Ziepert, M; Mann, B; Schoenwiese, U; Martin Montanez, L; Roskothen, M; Keil, C; Kunert, M; Wicklein, B; Döken, B; Schmiegel, W; Vetter, H; Pflüer, K; Steinhauer, H; Trüper, L; E...     »
Abstract:
We aimed to determine safety and efficacy of rituximab (R) in combination with repetitive high-dose therapy (HDT) as primary treatment for diffuse large B-cell lymphoma (DLBCL).Patients aged 18-60 years and elevated lactate dehydrogenase were treated with four cycles of MegaCHOEP and transplantation of autologous stem cells after cycles 2, 3 and 4. Rituximab (375 mg/m²) was given before each cycle and 12 and 33 days after start of the last cycle of chemotherapy. Sixty-four patients given R-MegaC...     »
Journal title abbreviation:
Ann Oncol
Year:
2010
Journal volume:
21
Journal issue:
11
Pages contribution:
2255-61
Language:
eng
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/20444844
Print-ISSN:
0923-7534
TUM Institution:
III. Medizinische Klinik und Poliklinik
 BibTeX